Drug Type CpG ODN |
Synonyms- |
Target |
Mechanism TLR9 agonists(Toll like receptor 9 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Duet BioTherapeutics, Inc.Startup |
Active Organization Duet BioTherapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | Duet BioTherapeutics, Inc.Startup | - |
Bladder Cancer | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Colonic Cancer | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Diffuse Large B-Cell Lymphoma | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Follicular Lymphoma | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Head and Neck Neoplasms | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Leukemia | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Mantle-Cell Lymphoma | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Marginal Zone B-Cell Lymphoma | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |
Melanoma | Discovery | US | Duet BioTherapeutics, Inc.Startup | - |